Seqent is an always-on AI agent that monitors scientific literature, genomic databases, and biotech pipelines to surface actionable drug target and biomarker opportunities — automatically, continuously, at a price small biotechs and academic labs can actually afford.
Big pharma pays millions for enterprise AI drug discovery platforms. Insilico, Isomorphic Labs, Exscientia — all built for the Fortune 500. Small biotechs and academic labs have the same scientific questions, the same data, and no budget.
They resort to manual literature reviews, fragmented databases, and gut instinct. The result: slower target validation, missed opportunities, and competitive disadvantage against well-funded incumbents.
Every week without an up-to-date target landscape is a week your competitors are ahead.
Define your therapeutic area, preferred target classes, biomarker types, and competitive watchlist. Seqent learns what matters to your research program.
Seqent crawls PubMed, ClinicalTrials.gov, TCGA, GEO, and genomic databases every day — automatically. No manual search, no alerts fatigue.
Every week: a ranked briefing of new target opportunities, biomarker signals, and pipeline threats — with supporting evidence, novelty scores, and relevance to your program.
Each briefing includes gene-disease evidence chains, competitive landscape context, and suggested validation approaches — ready to present to your scientific team.
Surfaces new publications, grants, and patent filings relevant to your target space — daily, automatically, without keyword alerts.
Queries TCGA, GEO, and other genomic repositories for expression signatures, mutation burden, and biomarker correlation data relevant to your targets.
Tracks competitive programs in ClinicalTrials.gov, maps mechanism-of-action landscapes, and flags when a competitor enters your target space.
Scores targets on novelty, tractability, competitive saturation, and biomarker evidence — ranked weekly, with full reasoning exposed.
Unique integration of human endogenous retrovirus data — an emerging target class in oncology and rare diseases that no other AI platform currently incorporates.
Drill into any target for the full gene-disease hypothesis: supporting publications, expression data, pathway context, and comparable approved drugs.
Those platforms require million-dollar partnerships and dedicated integration teams. Seqent is a self-service subscription — onboard in an afternoon, not a quarter.
A single literature review takes weeks. Seqent runs continuously, 365 days a year, and delivers the same output in a weekly briefing — with ranking and scoring built in.
General AI tools hallucinate at the edges of biology. Seqent is trained on the scientific literature graph — every claim traces back to a source, every ranking has explainable reasoning.
Built by a drug discovery scientist with 50+ publications in Lancet, Nature, and Cancer Discovery — not a tech company pivoting into biotech.
Seqent is the analyst you can't afford to hire and the monitoring system you haven't had time to build. It's always running. It never misses a week. And it costs less than a single month of consultant time.